MDGL
$286.06
Revenue | $137.25Mn |
Net Profits | $-73.24Mn |
Net Profit Margins | -53.36% |
Madrigal Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $137.25Mn in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 32.84% jump in its revenue since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit jumped 50.36% since last year same period to $-73.24Mn in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -23.26% fall in its net profits since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -53.36% in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 7.21% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -6.28 |
EPS Estimate Current Year | -6.28 |
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -6.28 - a -52.26% fall from last quarter’s estimates.
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -6.28.
Earning Per Share (EPS) | -3.32 |
Return on Assets (ROA) | -0.26 |
Return on Equity (ROE) | -0.5 |
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 55.01% since last year same period to -3.32 in the Q1 2025. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 55.01% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Madrigal Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.26.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Madrigal Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.5.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-05-01 | -6.28 | -3.32 | 47.13% |